A treatment for severe nodular acne: a randomized investigator-blinded, controlled, noninferiority trial comparing fixed-dose adapalene/benzoyl peroxide plus doxycycline vs. oral isotretinoin
| Autor: | J, Tan, S, Humphrey, R, Vender, B, Barankin, M, Gooderham, N, Kerrouche, F, Audibert, C, Lynde, Derek, Woolner |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
Adult
Male medicine.medical_specialty Adolescent Adapalene/benzoyl peroxide Population Dermatology Benzoyl peroxide Naphthalenes Administration Cutaneous law.invention Young Adult Double-Blind Method Randomized controlled trial Adapalene law Acne Vulgaris medicine Humans Child Isotretinoin education Adverse effect education.field_of_study Benzoyl Peroxide business.industry Confidence interval Treatment Outcome Doxycycline Drug Therapy Combination Female Dermatologic Agents Onset of action business Gels medicine.drug |
| Zdroj: | British Journal of Dermatology. 171:1508-1516 |
| ISSN: | 0007-0963 |
| DOI: | 10.1111/bjd.13191 |
| Popis: | SummaryBackground Oral isotretinoin (ISO) is the gold standard for severe nodular acne. However, as some patients are unwilling or unable to take, or are intolerant to, ISO, other options are needed. Objectives To compare efficacy and safety of oral ISO vs. doxycycline 200 mg plus adapalene 0·1%/benzoyl peroxide 2·5% gel (D+A/BPO) in severe nodular acne over 20 weeks. Methods This was a multicentre, randomized, controlled, noninferiority investigator-blinded study involving 266 subjects. Results D+A/BPO showed a significantly earlier onset of action in reducing nodules, papules/pustules and total lesions at week 2. ISO was superior in reducing nodules (95·6% vs. 88·7%), papules/pustules (95·2% vs. 79·6%) and total lesions (92·9% vs. 78·2%; all P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text